World News: 07:00 GMT Wednesday 15th May 2019. [Oasmia Pharmaceutical AB via Globe Newswire via SPi World News]
“Due to outstanding issues in the review, and also to make sure that fact-based decisions can be made, the Board has decided to postpone the release of the year-end report,” says , Chairman of Oasmia.
The ongoing review includes both valuation issues in the balance sheet as well as strategic planning discussions. The latter are conducted in co-operation with former Chairman of the Board and the CFO.
The outcome of the review and initiatives initiated by Oasmia’s new Board will communicated to the market as soon as there is relevant information to be shared.
For further information, please contact IR@Oasmia.com
Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia
Globe Newswire: 07:00 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.